Read on Twitter
The new ABX supply chain is fragile and drying up. @ChelwestFT with @OllyTroise @mughal_nabeela @dr_luke_moore & team we have sought to best use the tools already available to use. We have repurposed some ABX to promote better AMS & improve patient outcomes #WAAW2020
Co-trimoxazole provides excellent activity against many non-E. coli Enterobacterales and a useful option for HA-infections. It is not without risk https://pubmed.ncbi.nlm.nih.gov/32220637/ Here we present the importance of day 3 K+ / SCr monitoring to detect for early AKI +/- hyperk+ for safer use
Cefazolin, a 1st Gen cephalosporin, is used globally but has very little use in the UK. Recently licensed, we added this to our formulary for MSSA invasive infection in patients with penicillin allergy https://bit.ly/3lLui8A
You can't beat-a-lactam for invasive MSSA as they say.
You can't beat-a-lactam for invasive MSSA as they say.
Cefepime, a 4th Gen ceph, is also available in the UK. It's stable to most AmpC producers, has robust MSSA activity and retains in vitro activity to many MDR-pseudomonas. Here our review highlights role of FEP in OPAT (stable in a pump!) and for MDRO https://bit.ly/32T9nJ2
We repurposed tigecycline as a once daily Rx for OPAT. This ultra-broad agent (VRE, MRSA, ESBL, CRO) may not be suitable for all pts but has a valuable niche role in management of complex (stable) MDRO infections. Here we present our data on pt outcomes https://bit.ly/2IPmCUc
As AMR evolves, we have less reliable empiric treatment options. BUT we do have many tools that can be repurposed to improve our patient's experience and outcomes.
@ChelwestFT AMS team we use all available tools to diversify prescribing and tailor therapy for our patients
@ChelwestFT AMS team we use all available tools to diversify prescribing and tailor therapy for our patients
